Evidence map›Paper›PMID 41945300›Full record

ArticleAnnals of surgical oncology2026

A Retrospective Examination of Neoadjuvant Chemotherapy for Metachronous Colorectal Peritoneal Metastases Prior to CRS/HIPEC.

Michael M Wach, Hannah Bank, Kathrine Kelly, Thien Le, Joshua Derby, Geoffrey Nunns, Amer H Zureikat, David L Bartlett, Steven A Ahrendt, James F Pingpank and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Michael M Wach *Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Hannah Bank *Department of Surgery, Massachusetts General Hospital, Boston, MA, USA.
Kathrine KellyDepartment of Surgery, Department of Surgical Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Thien LeDepartment of Surgery, Department of Surgical Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Joshua DerbyDepartment of Surgery, Department of Surgical Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Geoffrey NunnsDepartment of Surgery, Department of Surgical Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Amer H ZureikatDepartment of Surgery, Department of Surgical Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
David L BartlettAHN Cancer Institute, Allegheny Health Network, Pittsburgh, PA, USA.
Steven A AhrendtDepartment of Surgery, University of Colorado, Aurora, CO, USA.
James F PingpankDepartment of Surgery, Department of Surgical Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Haroon A ChoudryDepartment of Surgery, Department of Surgical Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Melanie OngchinDepartment of Surgery, Department of Surgical Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. ongchinmc3@upmc.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNeoadjuvant chemotherapy (NACT) prior to cytoreductive surgery (CRS) and heated intraperitoneal chemoperfusion (HIPEC) for patients with metachronous colorectal peritoneal metastases (CRPM) carries theoretical advantages but thus far has not demonstrated survival benefit.

methodsWe conducted a retrospective single institution study of patients with CRPM undergoing CRS/HIPEC ± NACT from 2002 to 2022.

resultsA total of 199 patients with metachronous CRPM were identified; 128 patients (64.3%) underwent NACT while 71 patients (35.7%) underwent upfront CRS/HIPEC. The majority of patients were white (92.5%) and male (53.3%) with a median age of 57 years. There was an average of 19.5 months from initial colon cancer diagnosis to the development of CRPM, and 155 patients (77.9%) had undergone previous systemic chemotherapy in their disease course prior to development of CRPM. Patients who received NACT demonstrated no difference in PCI (median 12 vs. 10, p = .19) or rate of undergoing complete cytoreduction (81.2% vs. 93%, p = .08) versus those who underwent upfront CRS/HIPEC. Patients undergoing NACT+CRS/HIPEC experienced a significantly higher rate of major perioperative complications (25% vs. 12.7%, p = .04) and increased hospital length of stay (12 vs. 10 days, p < 0.01). There was no significant difference in median recurrence-free survival (18.7 vs. 20.3 months, p = .283) or overall survival (35.3 vs. 32.9 months, p = .513) between the groups.

conclusionsUtilizing NACT prior to CRS/HIPEC for patients with metachronous CRPM did not demonstrate survival benefit. NACT was, however, associated with increased rates of perioperative complications and length of hospital stay. Further studies are needed to better evaluate the optimal role and timing of systemic chemotherapy.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsCytoreduction Surgical ProceduresHyperthermia, InducedHyperthermic Intraperitoneal ChemotherapyNeoadjuvant TherapyNeoplasms, Second PrimaryPeritoneal NeoplasmsAdultAgedChemotherapy, AdjuvantCombined Modality TherapyFemaleFollow-Up StudiesHumansMaleColorectal peritoneal metastasesCRS/HIPECMetachronousNeoadjuvant chemotherapy

Identifiers

PMID41945300

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.